PE20190630A1 - Anticuerpos de anti-tim-3 - Google Patents
Anticuerpos de anti-tim-3Info
- Publication number
- PE20190630A1 PE20190630A1 PE2019000397A PE2019000397A PE20190630A1 PE 20190630 A1 PE20190630 A1 PE 20190630A1 PE 2019000397 A PE2019000397 A PE 2019000397A PE 2019000397 A PE2019000397 A PE 2019000397A PE 20190630 A1 PE20190630 A1 PE 20190630A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acids
- sequence
- whose
- refers
- Prior art date
Links
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 6
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 102000049109 human HAVCR2 Human genes 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 201000005296 lung carcinoma Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UN ANTICUERPO QUE SE UNE A LA PROTEINA TIM-3 HUMANA QUE COMPRENDE LAS REGIONES HIPERVARIABLES i) HCDR1 CUYA SECUENCIA DE AMINOACIDOS ES LA SEC ID NO: 2, ii) HCDR2 CUYA SECUENCIA DE AMINOACIDOS ES LA SEC ID NO: 3, iii) HCDR3 CUYA SECUENCIA DE AMINOACIDOS ES LA SEC ID NO: 4, iv) LCDR1 CUYA SECUENCIA DE AMINOACIDO ES LA SEC ID NO: 5, v) LCDR2 CUYA SECUENCIA DE AMINOACIDOS ES LA SEC ID NO: 6, Y vi) LCDR3 CUYA SECUENCIA DE AMINOACIDOS ES LA SEC ID NO: 7; ASI COMO UNA REGION VARIABLE DE CADENA PESADA CUYA SECUENCIA DE AMINOACIDOS ES LA SEQ ID NO: 8 Y UNA REGION VARIABLE DE CADENA LIGERA CUYA SECUENCIA DE AMINOACIDOS ES LA SEQ ID NO: 9. TAMBIEN SE REFIERE A UN PROCESO DE OBTENCION DE DICHO ANTICUERPO Y UNA COMPOSICION FARMACEUTICA UTIL PARA EL TRATAMIENTO DE CANCER DE PULMON, CABEZA Y CUELLO, RINON, VEJIGA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379343P | 2016-08-25 | 2016-08-25 | |
| US201762469753P | 2017-03-10 | 2017-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190630A1 true PE20190630A1 (es) | 2019-04-26 |
Family
ID=59772703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000397A PE20190630A1 (es) | 2016-08-25 | 2017-08-17 | Anticuerpos de anti-tim-3 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10253096B2 (es) |
| EP (1) | EP3504240B1 (es) |
| JP (1) | JP6502590B1 (es) |
| KR (1) | KR102142903B1 (es) |
| CN (1) | CN109563172B (es) |
| AU (1) | AU2017316473B2 (es) |
| BR (1) | BR112019001589A2 (es) |
| CA (1) | CA3035042A1 (es) |
| CL (1) | CL2019000488A1 (es) |
| CO (1) | CO2019001646A2 (es) |
| CR (1) | CR20190079A (es) |
| DO (1) | DOP2019000027A (es) |
| EC (1) | ECSP19013181A (es) |
| ES (1) | ES2908916T3 (es) |
| IL (1) | IL264159A (es) |
| JO (1) | JOP20190013A1 (es) |
| MA (1) | MA46041A (es) |
| MX (1) | MX2019002064A (es) |
| PE (1) | PE20190630A1 (es) |
| PH (1) | PH12019500369A1 (es) |
| SG (1) | SG11201900480YA (es) |
| TN (1) | TN2019000040A1 (es) |
| TW (2) | TWI639616B (es) |
| UA (1) | UA122929C2 (es) |
| WO (1) | WO2018039020A1 (es) |
| ZA (1) | ZA201900373B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10584167B2 (en) | 2015-03-23 | 2020-03-10 | Bayer Pharma Aktiengesellschaft | Anti-CEACAM6 antibodies and uses thereof |
| DK3443009T3 (da) | 2016-04-12 | 2021-12-13 | Symphogen As | Anti-tim-3-antistoffer og sammensætninger |
| AU2017297506A1 (en) | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
| JOP20190133A1 (ar) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| US20200024352A1 (en) * | 2016-12-08 | 2020-01-23 | Eli Lilly And Company | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies |
| CN110621698B (zh) | 2017-04-05 | 2024-04-12 | 法国施维雅药厂 | 靶向pd-1、tim-3及lag-3的组合疗法 |
| JOP20190222A1 (ar) * | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| WO2019196911A1 (en) | 2018-04-12 | 2019-10-17 | Nanjing Leads Biolabs Co., Ltd. | Antibody binding tim-3 and use thereor |
| JP2022513553A (ja) * | 2018-08-28 | 2022-02-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 抗ｔｉｍ３抗体医薬組成物およびその使用 |
| JP2022505925A (ja) * | 2018-11-01 | 2022-01-14 | メルク パテント ゲーエムベーハー | 抗ｔｉｍ－３抗体 |
| AU2019372436A1 (en) * | 2018-11-01 | 2021-05-20 | Merck Patent Gmbh | Methods of administering anti-TIM-3 antibodies |
| KR20210104704A (ko) | 2018-12-19 | 2021-08-25 | 바이엘 악티엔게젤샤프트 | 항 ceacam6 및 tim3 항체의 제약 조합물 |
| CN113272331A (zh) * | 2019-01-11 | 2021-08-17 | 伊莱利利公司 | 用于治疗癌症的tim-3抗体以及与其他检查点抑制剂的组合 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| CN113164601B (zh) * | 2019-09-19 | 2023-09-29 | 上药生物治疗（香港）有限公司 | 一种分离的抗原结合蛋白及其用途 |
| JP2023509516A (ja) | 2020-01-07 | 2023-03-08 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種 |
| EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
| RS66849B1 (sr) | 2020-12-28 | 2025-06-30 | Bristol Myers Squibb Co | Kompozicije antitela i postupci njihove upotrebe |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CA3230117A1 (en) | 2021-09-02 | 2023-03-09 | Mark Trautwein | Anti-cecam6 antibodies with reduced side-effects |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709412B2 (en) | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
| AU2003303082B2 (en) | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| US8647623B2 (en) * | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
| HUE040213T2 (hu) | 2010-06-11 | 2019-02-28 | Kyowa Hakko Kirin Co Ltd | Anti-TIM antitest |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| AU2015287969B2 (en) | 2014-07-07 | 2020-07-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
| SG11201703403TA (en) * | 2014-10-27 | 2017-05-30 | Agency Science Tech & Res | Anti-tim-3 antibodies |
| GB201419094D0 (en) * | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| CN107001475B (zh) * | 2014-11-06 | 2021-01-29 | 豪夫迈·罗氏有限公司 | 抗tim3抗体及使用方法 |
| US10822414B2 (en) * | 2014-11-11 | 2020-11-03 | Sutro Biopharma, Inc. | Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies |
| CN104592388B (zh) * | 2015-03-02 | 2017-05-31 | 中国人民解放军总医院 | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 |
| SG10201909173PA (en) | 2015-04-01 | 2019-11-28 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| JOP20190133A1 (ar) * | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| US20200024352A1 (en) * | 2016-12-08 | 2020-01-23 | Eli Lilly And Company | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies |
| JOP20190222A1 (ar) * | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
-
2017
- 2017-06-16 JO JOP/2019/0013A patent/JOP20190013A1/ar unknown
- 2017-08-14 TW TW106127417A patent/TWI639616B/zh not_active IP Right Cessation
- 2017-08-14 TW TW107134877A patent/TW201900684A/zh unknown
- 2017-08-17 WO PCT/US2017/047261 patent/WO2018039020A1/en not_active Ceased
- 2017-08-17 BR BR112019001589A patent/BR112019001589A2/pt not_active IP Right Cessation
- 2017-08-17 ES ES17761633T patent/ES2908916T3/es active Active
- 2017-08-17 CA CA3035042A patent/CA3035042A1/en not_active Abandoned
- 2017-08-17 US US15/679,190 patent/US10253096B2/en active Active
- 2017-08-17 SG SG11201900480YA patent/SG11201900480YA/en unknown
- 2017-08-17 KR KR1020197005011A patent/KR102142903B1/ko not_active Expired - Fee Related
- 2017-08-17 UA UAA201901191A patent/UA122929C2/uk unknown
- 2017-08-17 EP EP17761633.1A patent/EP3504240B1/en active Active
- 2017-08-17 TN TNP/2019/000040A patent/TN2019000040A1/en unknown
- 2017-08-17 MA MA046041A patent/MA46041A/fr unknown
- 2017-08-17 JP JP2018552182A patent/JP6502590B1/ja active Active
- 2017-08-17 CN CN201780052147.7A patent/CN109563172B/zh active Active
- 2017-08-17 AU AU2017316473A patent/AU2017316473B2/en not_active Ceased
- 2017-08-17 CR CR20190079A patent/CR20190079A/es unknown
- 2017-08-17 MX MX2019002064A patent/MX2019002064A/es unknown
- 2017-08-17 PE PE2019000397A patent/PE20190630A1/es unknown
-
2019
- 2019-01-09 IL IL264159A patent/IL264159A/en unknown
- 2019-01-18 ZA ZA2019/00373A patent/ZA201900373B/en unknown
- 2019-02-07 DO DO2019000027A patent/DOP2019000027A/es unknown
- 2019-02-21 PH PH12019500369A patent/PH12019500369A1/en unknown
- 2019-02-22 CO CONC2019/0001646A patent/CO2019001646A2/es unknown
- 2019-02-22 CL CL2019000488A patent/CL2019000488A1/es unknown
- 2019-02-22 EC ECSENADI201913181A patent/ECSP19013181A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| PE20191045A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer |